RNAZ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 22:39):

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease...

Stats
Dzisiejszy wolumen	1.08M
Średni wolumen	509 146
Kapitalizacja rynkowa	3.93M
EPS	$0 ( 2024-03-29 )
Następna data zysków	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00200 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-28	Fitzgerald Thomas A	Buy	49 350	Common Stock
2023-09-28	Dudley Robert Michael	Buy	98 000	Common Stock
2023-06-21	Dudley Robert Michael	Buy	12 000	Common Stock
2023-06-20	Dudley Robert Michael	Buy	6 607	Common Stock
2023-06-09	Dudley Robert Michael	Buy	19 000	Common Stock

INSIDER POWER
100.00
Last 36 transactions
Buy: 2 048 457 \| Sell: 1 170 653

Wolumen Korelacja

Długi: 0.36 (neutral)

Krótki: -0.23 (neutral)

Signal:(42.449) Neutral

TransCode Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje
APOP	0.933
MAGS	0.88
CMLF	0.856
RMRM	0.838

10 Najbardziej negatywne korelacje
MXIM	-0.807
MMAC	-0.805
WLTW	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TransCode Therapeutics, Korelacja - Waluta/Towar

0.51
( weak )

0.46
( neutral )

0.00
( neutral )

0.51
( weak )

-0.84
( strong negative )

-0.45
( neutral )

TransCode Therapeutics, Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2023
Przychody:	$0
Zysk brutto:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2022
Przychody:	$0
Zysk brutto:	$-98 606.00 (0.00 %)
EPS:	$-2 165.71

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.133

Financial Reports:

No articles found.

TransCode Therapeutics,

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.